# PTC Therapeutics, Inc.

**PTCT**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001070081

**D**

**fourth fifth of 370 graded peers in healthcare**

rank 250 of 370; percentile 67.5; sampling error 2.5 points; lower is stronger

A B C D E

**D, the sloth**



## Scoreboard

| | |
|---|---|
| **Profitability** | D/E<br>percentile 78.2 |
| **Solvency** | C<br>percentile 51.1 |
| **Growth and financing** | B<br>percentile 31.9 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $2.9B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: fortress balance sheet |
| **Inputs computable** | 8 of 14 |
| **Graded from** | filings received through Feb 19, 2026<br>253 days before the rescan; latest periodic filing 10-Q received Oct 29, 2026 |
| **Last close** | $64.50<br>2026-10-29; market equity $5.4B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 19, 2026*

Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are marketing or developing or that would render our products or product candidates obsolete or non-competitive. Our competitors may also obtain marketing authorization for their products more rapidly than we may obtain approval for our products and product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 78.2** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (1.2%) | (6.6%) | 78.2 | 805 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 1* | | | | | |
| **Solvency, sleeve percentile 51.1** | | | | | |
| Twelve-month failure probability | 0.10% | 0.07% | 55.9 | 246 | 2026-09-30 |
| Altman Z double-prime | 1.56 | (0.33) | 30.7 | 751 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 2.35x | 2.94x | 66.7 | 832 | 2025-12-31 |
| **Growth and financing, sleeve percentile 31.9** | | | | | |
| Revenue growth, three-year compound | 35.3% | 10.1% | 19.4 | 413 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | 57.8% | 37.1% | 41.7 | 104 | 2025-12-31 |
| Asset growth, three years | 19.3% | 2.1% | 21.8 | 697 | 2025-12-31 |
| Net share issuance, one year | 5.0% | 2.5% | 44.8 | 633 | 2026-02-18 |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 245 | Angiodynamics Inc. (ANGO) | 66.1 | D | fortress balance sheet |
| 246 | AIM ImmunoTech Inc. (AIM) | 66.4 | D | late filer, degenerate inputs, distress |
| 247 | Exagen Inc. (XGN) | 66.7 | D | dilution, fortress balance sheet |
| 248 | Amylyx Pharmaceuticals, Inc. (AMLX) | 66.9 | D | short runway, degenerate inputs |
| 249 | Alpha Teknova, Inc. (TKNO) | 67.2 | D | |
| 250 | PTC Therapeutics, Inc. (PTCT) | 67.5 | D | |
| 251 | American Shared Hospital Services (AMS) | 67.8 | D | late filer |
| 252 | U S Physical Therapy Inc. (USPH) | 68.0 | D | |
| 253 | Adaptive Biotechnologies Corp. (ADPT) | 68.3 | D | |
| 254 | Orchestra BioMed Holdings, Inc. (OBIO) | 68.6 | D | dilution, short runway, fortress balance sheet |
| 255 | Iridex Corp. (IRIX) | 68.8 | D | fortress balance sheet |

## What the price implies

*at the 2026-10-29 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 13.3% | 7.7% | 53 |
| Distance from 52-week high | (28.0%) | (26.6%) | 47 |
| EBIT to enterprise value | 17.4% | (1.4%) | 97 |
| Free cash flow yield | 13.0% | (0.9%) | 94 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Book value to price | (0.04) | 0.27 | 9 |
| Sales to price | 0.32 | 0.30 | 53 |
| Composite equity issuance, five years | 17.2% | 20.5% | 47 |
| Relative strength against the sector, log excess return | (0.09) | (0.14) | 53 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $508.9M |
| Operating cash flow, four quarters | $10.5M |
| Months of runway | not finite |
| Days since last periodic filing | 1 (10-Q received Oct 29, 2026) |
| Median daily dollar volume, 63 sessions | $65.7M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAs... | $307.0M | 2019-12-31 | 2020-03-02 | 10-K | 20-000064 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $12.1M | 2019-12-31 | 2020-03-02 | 10-K | 20-000064 |
| 3 | assets | us-gaap:Assets | $1.6B | 2019-12-31 | 2021-02-25 | 10-K | 21-000009 |
| 4 | net income | us-gaap:NetIncomeLoss | $682.6M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $711.2M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 6 | assets | us-gaap:Assets | $2.9B | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 7 | assets | us-gaap:Assets | $1.7B | 2024-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 8 | current assets | us-gaap:AssetsCurrent | $2.3B | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $968.4M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$3.0B | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | $866.9M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 12 | book equity | us-gaap:StockholdersEquity | -$205.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 13 | liabilities | us-gaap:Liabilities | $3.1B | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.7B | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $806.8M | 2024-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $937.8M | 2023-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $698.8M | 2022-12-31 | 2025-02-27 | 10-K | 25-000012 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $8.9M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$107.7M | 2024-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $6.5M | 2024-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$158.4M | 2023-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $28.4M | 2023-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$356.7M | 2022-12-31 | 2025-02-27 | 10-K | 25-000012 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $32.0M | 2022-12-31 | 2025-02-27 | 10-K | 25-000012 |
| 25 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $38.8M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 26 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $696.6M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 27 | income tax | us-gaap:IncomeTaxExpenseBenefit | $14.0M | 2025-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 28 | current assets | us-gaap:AssetsCurrent | $1.4B | 2024-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 29 | current liabilities | us-gaap:LiabilitiesCurrent | $581.0M | 2024-12-31 | 2026-02-19 | 10-K | 26-017575 |
| 30 | assets | us-gaap:Assets | $1.9B | 2023-12-31 | 2025-02-27 | 10-K | 25-000012 |
| 31 | assets | us-gaap:Assets | $1.7B | 2022-12-31 | 2024-02-29 | 10-K | 24-002196 |
| 32 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 82,774,730 | 2026-02-18 | 2026-02-19 | 10-K | 26-017575 |
| 33 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 78,869,368 | 2025-02-25 | 2025-02-27 | 10-K | 25-000012 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.